Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

圣地亚哥 - 专注于3D人体组织模型的生物科技公司Organovo Holdings, Inc. (NASDAQ: ONVO )已达成协议，将其FXR项目（包括主要资产FXR314）出售给制药巨头礼来公司 (NYSE: LLY )。礼来目前市值达到7 ...

US pharma major Eli Lilly has announced a deal with San Diego-based Organovo Holdings, a biotech focused on developing novel ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314.

智通财经APP获悉，Organovo Holdings今日宣布，礼来(LLY.US)（Eli Lilly and ...

礼来公司宣布收购Organovo旗下的FXR项目及其主打疗法FXR314，这是一款用于治疗溃疡性结肠炎等疾病的潜在“best-in-class”口服FXR小分子激动剂。Organovo已获得美国FDA的临床试验许可，正在进行2期试验，并计划将其应用于 ...

Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...